User profiles for "author:Ryan Fields"

Ryan C. Fields, MD

Professor & Chief of Surgical Oncology, Barnes-Jewish Hospital, Alvin J. Siteman …
Verified email at wustl.edu
Cited by 17652

[PDF][PDF] The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution

O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy… - Cell, 2020 - cell.com
Crucial transitions in cancer—including tumor initiation, local expansion, metastasis, and
therapeutic resistance—involve complex interactions between cells within the dynamic …

[HTML][HTML] Tumor-on-chip modeling of organ-specific cancer and metastasis

N Del Piccolo, VS Shirure, Y Bi… - Advanced drug delivery …, 2021 - Elsevier
Every year, cancer claims millions of lives around the globe. Unfortunately, model systems
that accurately mimic human oncology–a requirement for the development of more effective …

Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery

KA Bickenbach, PJ Karanicolas, JB Ammori… - The American Journal of …, 2013 - Elsevier
Background The aim of this study was to examine whether midline, paramedian, or
transverse incisions offer potential advantages for abdominal surgery. Data Sources We …

[PDF][PDF] Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression

Y Zhu, JM Herndon, DK Sojka, KW Kim, BL Knolhoff… - Immunity, 2017 - cell.com
Tumor-associated macrophages (TAMs) are essential components of the cancer
microenvironment and play critical roles in the regulation of tumor progression. Optimal …

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced …

TM Nywening, A Wang-Gillam, DE Sanford… - The lancet …, 2016 - thelancet.com
Background In pancreatic ductal adenocarcinoma, the CCL2–CCR2 chemokine axis is used
to recruit tumour-associated macrophages for construction of an immunosuppressive tumour …

NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines

SM Swetter, JA Thompson, MR Albertini… - Journal of the National …, 2021 - jnccn.org
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …

[PDF][PDF] Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer

S Hegde, VE Krisnawan, BH Herzog, C Zuo… - Cancer cell, 2020 - cell.com
Here, we utilized spontaneous models of pancreatic and lung cancer to examine how
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen …

Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in …

TM Nywening, BA Belt, DR Cullinan, RZ Panni, BJ Han… - Gut, 2018 - gut.bmj.com
Objective Chemokine pathways are co-opted by pancreatic adenocarcinoma (PDAC) to
facilitate myeloid cell recruitment from the bone marrow to establish an immunosuppressive …

Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology

DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

[HTML][HTML] Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer

D Cui Zhou, RG Jayasinghe, S Chen, JM Herndon… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and
poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …